Barrier effect of Esoxx® on esophageal mucosal damage: experimental study on ex-vivo swine model by Di Simone, Massimo P et al.
© 2012 Di Simone et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical and Experimental Gastroenterology 2012:5 103–107
Clinical and Experimental Gastroenterology
Barrier effect of Esoxx® on esophageal mucosal 
damage: experimental study on ex-vivo  
swine model
Massimo P Di Simone1
Fabio Baldi2,3
Valentina Vasina4
Fabrizio Scorrano5
Maria Laura Bacci5
Antonella Ferrieri6
Gilberto Poggioli1
1Department of General Surgery 
and Transplants, 2Centre for the 
Study and Therapy of the Esophageal 
Diseases, 3GVM Care and Research, 
MCH Cotignola (RA), 4Department of 
Pharmacology, Alma Mater Studiorum, 
University of Bologna, Bologna, 
5Department of Veterinary Medical 
Science – DMSVET – University of 
Bologna, Bologna, 6Clinical Research 
Department, Alfa Wassermann Spa, 
Bologna, Italy
Correspondence: Massimo P Di Simone 
Department of General Surgery and 
Transplants Alma Mater Studiorum 
University of Bologna,  
Via Massarenti 9, 40138 Bologna, Italy 
Tel +39 051 63 63 359 
Fax +39 051 63 64 207 
Email massimo.disimone@unibo.it
Abstract: The aim of the present study was to assess the potential barrier effect of Esoxx®, a 
new nonprescription medication under development for the relief of gastroesophageal reflux 
symptoms. Esoxx is based on a mixture of hyaluronic acid and chondroitin sulfate in a bioadhesive 
suspension of Lutrol® F 127 polymer (poloxamer 407) which facilitates the product adhesion 
on the esophageal mucosa. The mucosal damage was induced by 15 to 90 minutes of perfusion 
with an acidic solution (HCl, pH 1.47) with or without pepsin (2000 U/mL, acidified to pH 2; 
Sigma-Aldrich). Mucosal esophageal specimens were histologically evaluated and Evans blue 
dye solution was used to assess the permeability of the swine mucosa after the chemical injury. 
The results show that: (1) esophageal mucosal damage is related to the perfusion time and to the 
presence of pepsin, (2) mucosal damage is associated with an increased permeability, documented 
by an evident Evans blue staining, (3) perfusion with Esoxx is able to reduce the permeability 
of the injured mucosa, even after saline washing of the swine esophagus. These preliminary 
results support further clinical studies of Esoxx in the topical treatment of gastroesophageal 
reflux symptoms.
Keywords: bioadhesion, hyaluronic acid, Evans blue dye, animal model, esophagus, reflux 
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Introduction
Esoxx® (Alfa Wassermann, Bologna, Italy) is a new medical device for the topical 
treatment of the symptoms of gastroesophageal reflux disease (GERD). The product 
is based on a mixture of hyaluronic acid (HA) and chondroitin sulfate (CS) in a bio-
adhesive carrier Lutrol® F 127 (poloxamer 407) (BASF, Milan, Italy), which acts as a 
buffering agent to form a barrier and to prolong the action on esophageal mucosa.1
Hyaluronic acid (hyaluronan; HA) is a glycosaminoglycan made up of glucuronic 
acid and N-acetylglucosamine disaccharide units. HA is mainly present in the 
extracellular matrix of soft connective tissues and is involved in several key processes, 
including cell signaling, wound repair and regeneration, morphogenesis, matrix 
organization and pathobiology.2 Clinically, it is largely used for the treatment of several 
diseases. Topical HA preparations are applied in the management of recurrent aphthous 
ulceration, with immediate reduction of symptoms due to its barrier effect.2–4
Chondroitin sulfate (CS) is a natural glycosaminoglycan present in the extracellular 
matrix and is formed by the 1–3 linkage of D-glucuronic acid to N-acetylgalactosamine. 
The mechanism of action of CS explains its beneficial effect on the cartilage, synovial 
membrane and subchondral bone. CS may be of benefit in diseases where inflammation 
is an essential marker.5,6
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For its component characteristics, Esoxx® is proposed as a 
protective topical agent towards esophageal and gastric lesions 
as demonstrated in a preliminary report which shows that its 
oral administration may significantly improve symptoms in 
a group of patients affected by GERD or gastritis.7 Given 
that a direct evaluation of the barrier effect of this product on 
the esophageal mucosa is lacking, we attempted to prove its 
efficacy in an ex-vivo swine esophagus with a model similar to 
that previously used for evaluating the esophageal bioadhesion 
of alginate suspensions.8 To induce mucosal lesions, we used 
the perfusion of acid solutions, with and without pepsin. The 
aim of our study was to assess the barrier effect of Esoxx on 
swine esophageal mucosa after damage similar to that observed 
as a consequence of gastroesophageal reflux.
Materials and methods
Experimental animal procedure
Thirty swine esophagi were obtained from commercially 
available European breed pigs, weighing about 120 kg, 
slaughtered for food purposes. The pig esophagi arrived at 
the laboratory within 2 hours from the local slaughter house. 
Each esophagus was washed with tap water and the mucosa 
isolated from the muscularis mucosae and kept in vital 
condition on an oblique polystyrene surface (45°) at 37°C 
in a thermostated hood.
The tube of esophageal mucosa was cannulated and the 
top was tied with a surgery suture to a syringe connected 
to a perfusion pump. The perfusion rate was set to a rate 
of 1 mL/min. The distal end was closed for 5 minutes to 
completely fill the tube (Figure 1).
Damaging solutions
Esophageal mucosal damage was induced through perfusion 
with hydrochloric acid solutions in the presence or absence 
of pepsin as suggested by previous experimental studies.9,10 
The acid solution (AS) was prepared with HCl 0.1 N in sterile 
saline (pH 1.47). The pepsin solution (PS) was prepared by 
adding porcine pepsin (1%, 2000 U/mL; Sigma-Aldrich, 
St Louis, MO) to sterile normal saline acidified to pH 2 with 
HCl 0.1 N.
Esophagi were perfused at 37°C for 15, 30, 60, and 
90 minutes with AS; and for 15, 30, and 60 minutes with PS. 
Each procedure was repeated on three different esophagi.
Assessment of mucosal injury
At the end of each time point of perfusion, three specimens 
of mucosal rings were cut and fixed. Whole-wall mucosa 
samples were fixed in cold neutral formaldehyde 4% for 
1 hour and then placed in 200 mL Dulbecco’s phosphate-
buffered saline 25% sucrose at 4°C for cryoprotection, and 
finally embedded in optimal cutting temperature tissue 
freezing medium. Five-micron-thick sections of mucosa 
were cut, serially mounted on glass, and processed for routine 
hematoxylin–eosin staining.
Preparations, mounted with Mowiol® 4-88 reagent 
(Calbiochem, Giessen, Germany), were examined by 
light microscopy; representative photomicrographs were 
taken using a DS-5M digital camera (Nikon Instruments, 
Florence, Italy).
The mucosal damage severity was classified according 
to the following scores: Grade 0, no damage; Grade 1, (mild 
damage) erosion involving less than 10% of mucosal area, 
localized on superficial epithelial layers; Grade 2, (moderate 
damage) erosion involving 10% to 50% of mucosal area, 
localized on superficial layers, with dropout of keratinic cells; 
Grade 3, (severe damage) erosion involving more than 50% 
of mucosal area and extending through .50% of epithelial 
stratified layer.
Assessment of mucosal permeability  
and evaluation of the barrier effect  
of Esoxx
In order to assess the permeability of esophageal mucosa, the 
Evans blue (EB) dye solution was used. EB is known to bind 
to albumin in vivo and in vitro and is used as an indicator of 
vascular11 and intestinal permeability.12 In our experiment, we 
perfused with EB (10 mg/mL in sterile saline) both undam-
aged esophagi (negative control) and esophagi with severe 
mucosal lesions (see above) to allow EB penetration within 
the mucosal layer.
The damaged mucosa was washed with saline for 
5 minutes and divided into three portions. The first 
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Figure 1 Experimental model.Clinical and Experimental Gastroenterology 2012:5
(used as positive control) was perfused with EB (10 minutes 
at 1 mL/minute); the second, with Esoxx (10 minutes, 
1 mL/minute) followed by EB (10 minutes at 1 mL/minute). 
The third segment was perfused with Esoxx (10 minutes at 
1 mL/minute), then washed with saline for 30 seconds, and 
finally perfused with EB (10 minutes at 1 mL/minute). This 
last experiment aimed to assess the adhesive property of 
Esoxx (Figure 2).
The presence of EB staining was evaluated by light 
microscopy and scored with a 3-point scale: 0 (no stain); 
1 (weak stain); 2 (strong stain). We used two undamaged 
esophagi for the negative control and six esophagi with 
severe mucosal lesions.
Results
Assessment of mucosal injuries
The severity of the lesions induced by damaging solutions 
on the swine esophageal mucosa is shown in Table 1. The 
perfusions were performed on three different esophagi 
and three specimens were obtained from each of them. 
Nine mucosal specimens were examined for each experi-
mental group.
Histologic damage was found to be directly related to per-
fusion time. The acidic solution alone, perfused for 15 minutes, 
did not give rise to evident histological damage, while more 
prolonged perfusion caused a progressive involvement of 
the inner mucosal layers. Adding pepsin to the acid solution 
during the damage induction phase produced an appearance 
of histological damage at earlier time points. Severe histologi-
cal lesions were always observed after AS and PS perfusion 
for 90 and 60 minutes, respectively. Figure 3 shows some 
examples of the different degrees of damaged mucosa.
Assessment of mucosal permeability  
and evaluation of the barrier effect  
of Esoxx
Results of EB staining on different mucosal samples are 
  presented in Table 2. No EB staining was detected on the 
epithelial layer of control mucosa, while EB staining was 
evident in all the samples of damaged mucosa with 67% of 
them showing a strong stain. Perfusion of Esoxx after damaging 
acid solution for 90 minutes and pepsin solution for 60 minutes 
was able to completely prevent the EB staining in all the 
mucosal samples examined (Figure 4). This effect of Esoxx 
was not reversed by a short period of saline perfusion.
Discussion
Previous experimental studies carried out both in vitro13 and 
in vivo in animal models9,10 have clearly demonstrated that 
perfusion with solutions containing HCl and pepsin may 
induce esophageal mucosal damage that mimics the lesions 
induced by gastroesophageal reflux. Porcine esophagus is con-
sidered an appropriate model for ex-vivo studies and has been 
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Figure 2 Perfusion sequences used for the evaluation of mucosal permeability and 
Esoxx effect.
Abbreviation: EB, Evans blue dye.
Table 1 Severity of histological damage induced with acidic and 
pepsin solutions
Time  
(min)
Grade 0 Grade 1 Grade 2 Grade 3
Acidic 
solution
15 9 (100%) – – –
30 1 (11%) 7 (78%) 1 (11%) –
60 – 1 (11%) 7 (78%) 1 (11%)
90 – – – 9 (100%)
Pepsin 
solution
15 – 7 (78%) 2 (22%) –
30 – – 7 (78%) 2 (22%)
60 – – – 9 (100%)
Notes: Data expressed as absolute frequency (%) of score attributed (grade 0 = 
no damage; grade 1 = mild damage; grade 2 = moderate damage; grade 3 = severe 
damage).
AB
CD
50 µm5 0 µm
50 µm 50 µm
Figure 3 Representative examples of cross-sections of esophageal mucosa (H&E) 
treated with saline (A) or different damaging solutions (B–D). (A) no damage 
(grade 0). (B) Acid solution (60 minutes): mild damage (grade 1) extended throughout 
one or two epithelial layers. (C) Pepsin solution (30 minutes); moderate damage 
(grade 2) mainly localized on superficial layers. A disorganization of epithelial layers 
was observed along the tissue, with some intact areas and areas in which erosion 
interested from 30% to 50% of mucosal thickness. (D) Acid solution (90 minutes); 
severe damage (grade 3) and complete erosion of keratinic epithelial layers, with 
injury extending through more than 50% of epithelial stratified layer.Clinical and Experimental Gastroenterology 2012:5
used in several experimental pharmacology studies to assess 
the adhesive property of drugs.14–16 As suggested in previous 
studies,8,17 it can be mounted as a mucosal tube in order to 
reproduce a kind of flow along the esophageal lumen. In our 
study we used acidic solutions, with or without pepsin, perfused 
for different time periods in an ex-vivo swine model to induce 
esophageal mucosal damage. Mucosal lesions were assessed 
by applying a histologic score that took into account both the 
superficial extent and the depth of the mucosal damage. In our 
model, the severity of the lesions was directly influenced by the 
duration of the perfusion and by the presence of pepsin. This 
is in agreement with the results obtained with the perfusion of 
acidified pepsin of an in vivo rabbit esophagus.10
We found that the most severe lesions, characterized 
by erosions involving more than 50% of mucosal area 
and extending through more than 50% of the epithelial 
stratified layer, were observed in all the specimens perfused 
with acid solution for 90 minutes or with acid plus pepsin for 
60 minutes. We considered this a suitable and reproducible 
model to induce a chemical lesion of esophageal mucosa.
In normal conditions, the esophageal mucosa is   protected 
against injurious agents by its stratified, multilayered squamous 
epithelium which represents a true mucosal   barrier. All the 
damaging substances, such as hydrochloric acid and pepsin 
contained in the gastric refluxate, may impair this barrier and 
as a consequence may increase the mucosal permeability.18 In 
our experimental model we evaluated the esophageal mucosal 
permeability with a high-molecular-weight dye, EB, which has 
been extensively used to study microvascular permeability.11–19 
This dye has also been used as an endoluminal marker of 
mucosal permeability of the jejunum in rat12 and of the colon 
in mouse.20 These authors perfused EB for long periods of 
time (30 to 120 minutes) in in-vivo models and estimated 
the uptake of the dye into the gut wall, both qualitatively and 
quantitatively. Our study was carried out in different experi-
mental conditions (ex-vivo porcine esophagus) and with a 
short time of EB perfusion (10 minutes) of both a segment 
of undamaged esophagus (negative control) and segments of 
mucosa with severe lesions. Our results show that EB does not 
penetrate undamaged esophageal mucosa, while it is clearly 
detectable, even with light microscopy, in the specimens of 
mucosa damaged by acid and peptic solutions. For this reason, 
we tested the hypothesis that prevention of the increased 
permeability due to the presence of mucosal breaks could be 
accomplished with Esoxx, which can coat the damaged mucosa 
with its components, HA and CS. HA is an extraordinarily 
versatile glycosaminoglycan currently receiving attention 
across a wide range of research areas. It has a very high molar 
mass, usually in the order of millions of Daltons, and possesses 
interesting viscoelastic properties based on its polymeric and 
polyelectrolyte characteristics. Its length, coupled with its high 
hydrating property, allows many HA polymers to organize 
in a reticular structure, which in turn produces a molecular 
framework. Such scaffolding, besides supporting the tone 
and shape of tissues, acts as a filter to prevent the diffusion 
of high-molecular-weight substances and dissemination of 
infectious agents.2,21–24 CS may be of benefit in diseases where 
inflammation is an essential marker.6
The results showed that Esoxx perfused at 1 mL/minute 
for 10 minutes, after mucosal damage induction, preventing 
the penetration of the EB dye in the mucosa and acting as a 
topical mucosal barrier.
In addition, the ability of the bioadhesive polymer 
to produce a persistent mucosal barrier effect was also 
demonstrated after a brief washing of the esophageal mucosa 
with saline after perfusion with Esoxx.
The esophagus is an organ of transport with a very short 
transit time that does not favor drug contact or delivery. 
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Table 2 Evans blue (EB) staining on control tissue and damaged 
mucosa with or without Esoxx application
0 (no  
stain)
1 (weak 
stain)
2 (strong 
stain)
no damaged mucosa + EB 2 (100%) – –
Damaged mucosa + EB – 2 (33%) 4 (67%)
Damaged mucosa + Esoxx + EB 6 (100%) – –
Damaged mucosa + Esoxx +  
saline + EB
6 (100%) – –
Note: Data expressed as frequency of staining score observed in each experimental 
group (six mucosal samples).
AB
CD
20 µm2 0 µm
20 µm 20 µm
Figure 4 Representative examples of cross-sections of esophageal mucosa after EB 
perfusion. (A) no stain; undamaged mucosa + EB. (B) Weak stain; damaged mucosa 
(acid solution 90 minutes ) + EB. (C) Strong stain; damaged mucosa (pepsin solution 
60 minutes) + EB. (D) no stain; damaged mucosa (acid solution 90 minutes) + 
Esoxx + EB.
Note: no stain also in the damaged mucosa (pepsin solution 60 minutes) + Esoxx + EB.
Abbreviation: EB, Evans blue dye.Clinical and Experimental Gastroenterology
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Several pharmaceutical studies have been carried out to 
investigate bioadhesive dosage forms that adhere to esophageal 
mucosa and prolong contact. The retention of sucralfate or alg-
inate formulations were studied both with in-vitro models16,25 
and with ex-vivo porcine esophageal tube.8 To the best of our 
knowledge, there are no studies that have investigated the 
direct effect of topically acting drugs on esophageal mucosal 
lesions. In our experimental model perfusion with Esoxx for a 
relatively short time period was able to exert a barrier effect on 
the damaged esophageal mucosa by reducing its permeability. 
This effect should be looked at with interest given that the 
increased permeability due to chemical damage such as that 
induced by pathological gastroesophageal reflux, represents the 
main mechanism for the development not only of the mucosal 
breaks but also of symptoms (ie, heartburn, pain) even in the 
absence of detectable lesions.18
Further studies are needed to better evaluate the effect 
of this compound on the esophageal mucosal barrier and 
particularly its bioadhesive properties and the duration of the 
effect. If these preliminary results are clinically confirmed, 
the possibility of a new topical therapy to be included among 
the treatment options for the management of reflux disease 
should be evaluated.
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